Stock Events

Stock Events

Unity Biotechnology 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9U9.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Senseonics
SENS
Mkt Cap286.07M
Senseonics Holdings is involved in the development of medical devices, some of which target age-related diseases, overlapping with Unity's market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals works on RNAi therapeutics that can target a wide range of diseases, including those related to aging, competing with Unity's approach.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is focused on gene editing, a technology that can be applied to age-related diseases, making it a competitor in the longevity field.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine operates in the gene editing space, targeting diseases that can be related to aging, thus competing with Unity's therapeutic areas.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics focuses on precision genetic medicine, including therapies for diseases that become more prevalent with age, competing with Unity's focus.
Novartis
NVS
Mkt Cap305.1B
Novartis offers a broad range of healthcare solutions, including treatments for age-related diseases, making it a competitor in the longevity space.
Pfizer
PFE
Mkt Cap138.61B
Pfizer is a large pharmaceutical company with a diverse portfolio that includes treatments for age-related diseases, competing with Unity's focus.
Biogen
BIIB
Mkt Cap31.91B
Biogen focuses on neurodegenerative diseases, many of which are age-related, directly competing with Unity's approach to aging and disease.

About

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Anirvan Ghosh Ph.D.
Employees
65
Country
United States
ISIN
US91381U1016

Listings

MU
DE
9U9.MU
STU
DE
9U9.STU

0 Comments

Share your thoughts

FAQ

What is Unity Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Unity Biotechnology stocks are traded under the ticker 9U9.MU.
How many employees does Unity Biotechnology have?▼
As of July 11, 2026, the company has 65 employees.
In which sector is Unity Biotechnology located?▼
Unity Biotechnology operates in the Health & Wellness sector.
When did Unity Biotechnology complete a stock split?▼
Unity Biotechnology has not had any recent stock splits.
Where is Unity Biotechnology headquartered?▼
Unity Biotechnology is headquartered in South San Francisco, United States.